Johnson & Johnson vs Intellia Therapeutics, Inc. — Stock Comparison
Q·Score Breakdown
7.1
Bullish
Overall
6.2
Neutral
Quality
Health
Growth
Valuation
Sentiment
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
NTLA
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ low return on equity (-53%).
Analyst Consensus
BUY
Target $252.42 (+11.1%)
24 analysts
BUY
Target $26.71 (+101.5%)
21 analysts
Fundamentals
JNJ
NTLA
26.3×
Trailing P/E
—
17.9×
Forward P/E
-4.6×
21.8%
Profit Margin
0.0%
68.0%
Gross Margin
0.0%
26.4%
ROE
-53.5%
9.9%
Revenue Growth
78.8%
-52.9%
Earnings Growth
—
0.33
Beta
1.99
—
Price / Book
—
$546.9B
Market Cap
$1.6B
$146 – $252
52-Week Range
$7 – $28
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →